Global Quadrivalent Meningococcal Vaccine Market Growth 2024-2030

Global Quadrivalent Meningococcal Vaccine Market Growth 2024-2030

The meningococcal quadrivalent vaccine protects against 4 types of meningococcus: types A, C, Y, and W.

The global Quadrivalent Meningococcal Vaccine market size is projected to grow from US$ 181 million in 2023 to US$ 273.9 million in 2030; it is expected to grow at a CAGR of 6.1% from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “Quadrivalent Meningococcal Vaccine Industry Forecast” looks at past sales and reviews total world Quadrivalent Meningococcal Vaccine sales in 2023, providing a comprehensive analysis by region and market sector of projected Quadrivalent Meningococcal Vaccine sales for 2024 through 2030. With Quadrivalent Meningococcal Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Quadrivalent Meningococcal Vaccine industry.

This Insight Report provides a comprehensive analysis of the global Quadrivalent Meningococcal Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Quadrivalent Meningococcal Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Quadrivalent Meningococcal Vaccine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Quadrivalent Meningococcal Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Quadrivalent Meningococcal Vaccine.

Many countries have implemented meningococcal vaccination programs, especially targeting high-risk groups such as infants, adolescents and university students. Inclusion or recommendation of quadrivalent meningococcal vaccines in national immunization schedules can significantly influence the market demand.

This report presents a comprehensive overview, market shares, and growth opportunities of Quadrivalent Meningococcal Vaccine market by product type, application, key manufacturers and key regions and countries.

Segmentation by type
Polysaccharide Vaccine
Conjugate Vaccine

Segmentation by application
Hospital
Clinic

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sanofi-Pasteur
Walvax
Chengdu Kanghua Biological Products Co., Ltd.
Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd.
Zhejiang Tianyuan Biopharmaceutical Co., Ltd.
Beijing Institute of Biological Products Co., Ltd.
CanSino Biological Co., Ltd.
Hualan Biological Vaccine Co., Ltd.
Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Quadrivalent Meningococcal Vaccine market?

What factors are driving Quadrivalent Meningococcal Vaccine market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Quadrivalent Meningococcal Vaccine market opportunities vary by end market size?

How does Quadrivalent Meningococcal Vaccine break out type, application?

Please note: The report will take approximately 2 business days to prepare and deliver.